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Abstract 
Although testosterone replacement treatment (TRT) can improve sexual function in many 
hypogonadal (HG) men with type 2 diabetes (T2DM), some show either no improvement or only in a 
limited number of domains. Indeed, it is often difficult for the clinician to offer an indication of the likely 
efficacy of TRT as little data exists on the proportion of TRT-treated men who will demonstrate 
improvement in domains such as sexual desire (SxD) and erectile function (EF). We describe in men 
with T2DM firstly, the likelihood of improved sexual desire (SxD) and erectile function (EF) following 
TRT at various time points and secondly, if SxD change predicts later EF change. During a 30 week 
randomised controlled study of testosterone undecanoate (TU), 199 T2DM men with HG (189 men 
completing) identified from primary care registers (placebo (P): 107, TU: 92) were stratified using 
baseline Total Testosterone (TT)/Free Testosterone (FT) into Mild (TT 8.1–12nmol/l or FT 0.18-
0.25nmol/l) and Severe HG groups (TT ≤8nmol/l and FT ≤0.18nmol/l) and placebo (P) and TU treated 
groups. Associations between TU, SxD and EF were investigated using Chi square and logistic 
regression analysis.  TU improved SxD after 6 weeks while EF improvement occurred after 30 weeks, 
observations particularly evident in Severe HG men. Changes in SxD and EF were significantly 
associated in all groups. Logistic regression showed that SxD change at 6 weeks predicted of EF 
change after 30 weeks. Our study confirms TRT leads to changes in SxD and EF at different time 
points and, suggests SxD and EF changes are related. SxD change after 6 weeks predicting EF 
change at 30 weeks is possibly a useful clinical finding. 
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Introduction. 
Hypogonadism (HG) is common in men with Type 2 diabetes (T2DM) [1]. The condition is defined by 
low serum testosterone concentrations (<12 nmol/l) and sexual symptoms. Thus, Kapoor et al (2007) 
showed firstly, that 20% of 355 men with T2DM had total testosterone (TT) levels < 8nmol/l and 31%, 
levels between 8-12nmol/l [2] and secondly, using the Androgen Deficiency in the Aging Male 
questionnaire, significant levels of HG and erectile dysfunction (ED). Further, the Massachusetts Male 
Aging Study demonstrated a threefold increase in ED prevalence in men with T2DM compared with 
their non-diabetic counterparts [3]. To allow better quantification of ED and other aspects of sexual 
function, Rosen et al (1997) developed a validated self-administered 15 item International Index of 
Erectile Function (IIEF) questionnaire [4] that examines 5 domains; erectile function, intercourse 
satisfaction, orgasmic function, sexual desire (SxD) and overall satisfaction. Prevalence of ED in 
T2DM men, assessed using the IIEF questionnaire is estimated to be >70% [1]. 
 
The different domains are affected at varying testosterone levels with loss of libido, depression/T2DM 
in non-obese men and decreased EF more common at TT concentrations <15nmol/l, <10nmol/l and 
<8nmol/l respectively [5]. Thus, as expected testosterone replacement therapy (TRT) has an 
important role in improving sexual function though its efficacy on different domains varies. Indeed, 
Yassin and Saad showed that while SxD improved in all 22 men with HG given 24 weeks of TRT, EF 
scores increased in only 54% of the men [6]. Further, the time taken for treatment to effect 
improvement in different domains varied. We reported in a primary care cohort of men with T2DM and 
Severe HG (TT < 8nmol/l, free testosterone (FT) <0.18nmol/l), that long-acting testosterone 
undecanoate (TU) was associated with significantly improved SxD after 6 weeks but EF only at 30 
weeks treatment [7]. TU was not associated with significantly improved SxD or EF in men with Mild 
HG. Cunningham et al showed in 470 men aged ≥65 years with average TT < 275 ng/dl (9.54 nmol/l) 
and low libido, that of 12 measures of sexual activity (evaluated via Psychosexual Daily 
Questionnaire, Derogatis Interview for Sexual Function and IIEF) only “flirting by others” and “day 
spontaneous erections” did not significantly improve following TRT for 1 year [8]. Further, increases in 
TT, FT and oestradiol concentrations were associated with improvement in SxD but not EF. Thus, the 
above studies demonstrate that TRT can significantly improve sexual function in men though the time 
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scale of benefit differs for different domains. Further, men may demonstrate improvement in one but 
not another domain. 
  
Importantly, while TRT can effect improved sexual function domain scores in men with T2DM, it is 
unclear what proportion of treated men demonstrate improvement and whether in one or more 
domains. This issue is important for patients particularly early on in treatment. Accordingly, we 
compared the proportion of T2DM men with HG demonstrating improvement following TRT in two 
ordinal domains, SxD and EF. As the efficacy of TRT appears influenced by baseline TT we 
investigated the effect in the total cohort and after stratification into Mild and Severe HG [7,9]. We 
describe the inter-relationships between treatment duration and improvements in EF and SxD and the 
proportions of men showing improvement in one or both domains. We also wished to determine if 
change in SxD at 6 weeks of TRT was predictive of improvement in EF at 30 weeks. If this was the 
case, clinicians might be able to indicate prognosis regarding EF relatively early during TRT. 
 
Patients and Methods. 
BLAST (acronym for patient recruitment from 7 primary care centres in Birmingham, Lichfield, 
Atherstone, Sutton Coldfield, Tamworth in the English midlands) describes a 30 week randomised 
double-blind placebo-controlled multicentre study carried out September 2008 - June 2012 to assess 
the impact of TRT on men with T2DM [9]. The 30 weeks study duration adhered to guidelines 
recommending TRT trial periods of 3–6 months in men with HG (10). The study was conducted in 
accordance with the revised guidelines of the World Medical Association Declaration of Helsinki 
(https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects/ - accessed on 02/05/2017). The study (EudraCT 2008-000931-
16) was approved by the Multicentre Research Ethics Committee (reference: 08/H1208/30), the 
National Institute for Health Research (Birmingham and the Black Country Comprehensive Local 
Research Park – RM&G reference: 1268) and Warwickshire Primary Care Trust (reference: 
WAR230909). 
Change in glycaemic control (HbA1c) was the primary efficacy end-point and several secondary end 
points included changes in IIEF scores [9]. The target sample size of 100 men in the TU treatment 
and placebo (P) arms had an 80% probability of demonstrating a statistically significant treatment 
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difference in the event of a treatment change in HbA1c of 0.4%. This calculation used a standard 
deviation of 1%, a significance level of 5% (two-sided), and analysis of covariance (ANCOVA) with 
baseline HbA1c as the covariate. HbA1c change of 0.4% was clinically accepted as significant and a 
SD (baseline corrected) of 1% was derived from previous trials. Physicians were asked, where 
possible, to avoid changes in diabetes, anti-hypertensive and lipid-lowering therapy during the study. 
Any patient requiring anti-coagulation was to be withdrawn. Adverse events were identified at each 
visit using a non-leading question. The safety assessment was to comprise all subjects recruited 
unless study medication was known not to have been taken, and the intention to treat population was 
to comprise all subjects in the safety population who provided efficacy data.  
Inclusion criteria included men aged 18–80 years with symptoms of HG defined by the Aging Male 
Symptom scale together with an initial TT ≤12.0nmol/l or FT ≤ 0.25nmo/l according to current 
European Association of Urology (EAU) guidelines [10]. Exclusion criteria included men considered 
too frail for TRT, previous TRT, abnormal digital rectal examination, PSA >4μg/L, haematocrit >0.50, 
history of prostate cancer or other serious co-morbidities.  From the primary care T2DM register, 550 
men with an 8–11 am TT level ≤12.0nmol/l or FT ≤ 0.25nmo/l  were approached (pre-screening) with 
488 men consenting to be screened (visit 1, Figure 1). At visit 1, eligibility was evaluated using the 
above criteria (including 2 TT and FT measurements taken at least 6 weeks apart). Of the eligible 211 
men, 11 were excluded (raised PSA: 10, atrial fibrillation: 1) and recruitment was closed when the 
target of 200 men was reached (Figure 1). One patient withdrew and the remaining199 men were 
randomised to 1000mgTU (HG/TU: 92 men) or matched Placebo (P) (HG/P: 107 men) at 0 (visit 2) 
and treated accordingly at 6 (visit 3), 18 (visit 4) and 30 weeks (visit 5). Exercise and dietary advice 
using standard NHS diabetes literature was administered at visit 1. Of the 199 men commencing the 
study, 189 men (HG/TU: 86, HG/P: 103) completed the 30 weeks (reasons for non-completion and 
adverse events shown in Figure 1). 
Men in the HG/TU and HG/P groups were stratified by 8-11 am TT and FT levels into Mild HG (TT: 
8.1 – 12 nmol/l or FT: 0.181– 0.25 nmol/l) and Severe HG (TT: ≤ 8.0 nmol/l and FT: ≤ 0.18 nmol/l) 
based on current EAU guidelines [10]. The 4 sub-groups were: 
1. Mild HG/Placebo (Mild HG/P):  51 patients 
2. Mild HG/TU (Mild HG/TU): 56 patients 
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3. Severe HG/placebo (Severe HG/P): 52 patients 
4. Severe HG/TU (Severe HG/TU): 30 patients 
The validated, full 15 item International Index of Erectile Function (IIEF) was used to assess EF (using 
questions 1-5 and 15) and SxD (questions 11-12) domains of sexual function [4]. 
Randomisation and treatment. 
Subjects were randomised to TU 1000 mg (HG/TU) or P (HG/P) into the right or left upper outer 
gluteal region. TU and P were prepared by the manufacturing company (trade name: Nebido) Bayer 
(Pharma AG, Berlin, Germany) and randomised in blocks via standard processes adopted during their 
development programme. Identification of trial medication was via numbered sealed packages with 
each individual assigned to the next lowest package. The code breaks were retained by the study 
statisticians until the last patient was recruited and the codes were broken after the final procedure 
and data bases were locked. The dose interval was in accordance with manufacturer’s 
recommendations (Figure 1). The P was an analogue of the same appearance minus active 
substance containing the vehicle castor oil and benzyl benzoate.  
Laboratory Testing. 
Morning (8-11 am) fasting blood samples were taken at screening visits, -2 (visit 1), 6 (visit 3), 18 (visit 
4), and 30 (visit 5) weeks for measurement of haematocrit, HbA1c and serum TT, sex hormone-
binding globulin (SHBG) and PSA. All measurements were carried out at the Heart of England 
Foundation NHS Trust Laboratories. TT was measured using a Roche Common Platform 
Immunoassay (validated against mass spectrometry). Serum SHBG, albumin and PSA levels were 
measured using a Roche Modular automated analyzer (Roche Diagnostics, Burgess Hill, UK). FT was 
calculated using an online calculator based on the equations of Vermeulen et al. [11].  
Statistical Analysis. 
IIEF sexual function scores were available in 176 men at visit 5 (30 weeks). Adjustment for multiple 
significance testing was not carried out as the secondary outcome end-points were regarded as 
exploratory. Changes between baseline and end of study TT and FT within each group was 
established with paired t-test. Baseline and end of study differences in characteristics between the 
stratified groups (HG/P vs HG/TU, Mild HG/P vs Mild HG/TU, Severe HG/P vs Severe HG/TU) were 
determined using unpaired t-tests (continuous variables) and Wilcoxon rank-sum test (ordinal IIEF 
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SxD and EF scores). Between group differences in the proportion of men showing improvement 
(compared to unchanged/decreasing scores) in SxD and EF at 6, 18 and 30 weeks were established 
by Chi Square analysis.  
Logistic regression was used to determine if improvement in SxD after 6 weeks predicted 
improvement in EF at 30 weeks. Receiver operated characteristic (ROC) curves were created for 
predictive models in the three groups by plotting the true positive rate (sensitivity) against the false 
positive (1-specificity) rates. The area under the curve was used to estimate the model’s ability to 
predict the outcome; we considered areas of 0.9-1.0, 0.8-0.9, 0.7-0.8 and 0.6-0.7 to be excellent, 
good, fair and poor respectively (http://gim.unmc.edu/dxtests/roc3.htm - accessed on 02/05/2017). All 
statistical analyses were carried out using Stata version 8 (College Station, TX).  
Results. 
Demographic data. 
Table 1 shows relevant variables at baseline in men randomised into HG/P and HG/TU groups and 
then allocated to corresponding groups with Mild or Severe HG. At baseline, no significant differences 
in any of these variables were observed between the HG/TU and HG/P groups or, in the stratified 
sub-groups (Mild HG/TU vs Mild HG/P, Severe HG/TU vs Severe HG/P). At 30 weeks, mean trough 
TT and FT levels in each TU group had increased significantly (HG/TU: p=0.0002, Mild HG/TU: 
p=0.0056, Severe HG/TU: p=0.013) compared with corresponding baseline values and, in the HG/TU 
(p=0.010) and Severe HG/TU (p=0.026) groups levels had significantly increased compared to 
corresponding men in the P group (Table 1).  
IIEF SxD and EF scores. 
Table 1 shows mean, median and range of values for SxD and EF scores at baseline and 30 weeks. 
At 30 weeks, mean values of SxD and EF were higher in the HG/TU and Severe HG/TU (but not Mild 
HG/TU) groups than in the corresponding controls. However, as previously reported only the increase 
in EF scores in HG/TU men (compared with HG/P) achieved significance (p=0.021) (7). 
Table 2 shows that in the HG/TU group the proportion of men with improved SxD scores was always 
significantly higher than in the HG/P men; indeed for this domain the difference between the 
proportion of treated and untreated men in the HG group achieving improved SxD scores was 
significant at 6 weeks (ie. prior to second TU injection) and thereafter. Similar results were observed 
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in the Severe HG group; an even higher proportion of treated men demonstrated increased SxD 
values at 6 weeks (Severe HG/P: 21.2%, Severe HG/TU: 60.0%, p<0.001), this difference widening 
thereafter (at 30 weeks Severe HG/P: 20.8%, Severe HG/TU: 74%).  No significant increase was 
observed in the Mild HG group (Table 2). Figures 2a and 2b show these data graphically. Table 2 also 
shows EF scores in the total HG group. At each time point the percentage of men with improved 
scores was higher in TU than P men though this difference was significant only at 30 weeks TRT. A 
similar association was seen in the Severe HG group; the difference in proportion of men 
demonstrating improved EF scores achieved significance only at 30 weeks. In the Mild HG group, no 
significant differences were observed between proportions of men in the P and TU groups (Table 2 
and Figures 2a, 2b).  
Relationship between changes in SxD, EF and TU. 
Table 3 shows in the HG/P and HG/TU groups, the numbers and percentages of men who showed no 
change/decrease or, increase in either or both SxD and EF. In the HG/P group, 62.5% men showed 
no change/decrease in both domains while only 15.6% demonstrated increased values in both SxD 
and EF. The impact of TRT is shown in the HG/TU group; the corresponding percentages were 35.0% 
and 33.8% (Table 3). TRT was also associated with a greater percentage of men demonstrating 
increase in only SxD (HG/P 7.3%, HG/TU 17.5%) though the percentages of men demonstrating only 
increased EF were similar in the two groups (HG/P 14.6%, HG/TU 13.8%). Similarly in the Severe HG 
group, 63.0% (17/27 men) HG/TU patients demonstrated increased SxD and EF compared with 
12.5% (6/48 men) of HG/P men. In Mild HG men, the percentages demonstrating improvement in 
both domains were similar (18.9% (Mild HG/TU) and 18.8% (Mild HG/P) though more men showed 
increased SxD with no change/decreased ED in the treated (20.8%) compared with placebo (6.3%) 
groups. 
The data in Table 3 show some evidence of a relationship between change in SxD and EF after TRT. 
In the Severe HG/TU men; TRT resulted in 63.0% of patients showing increased SxD and EF values 
and 25.9% recording no increase in either domain. Thus, in only 11.1% of men were the two domains 
not associated. However, the putative relationship appeared less clear in the Mild HG men with 41.6% 
of men demonstrating an increase in one but not the other domain. In the total HG group the 
corresponding figure was 31.3%. 
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Relationship between SxD at 6 weeks and EF at 30 weeks. 
Figure 2b shows how values of SxD and EF changed at 6, 18 and 30 weeks in men with Severe HG 
given either P or TU. In men given TU, the data show that while values for both domains increased 
with time, the increase in SxD was greater at each time point. Accordingly, we used logistic 
regression to determine if change in EF at 30 weeks treatment (dependent variable: increased versus 
no change/decreased) could be predicted by change in SxD score at 6 weeks. Table 4 shows that in 
the total group, the SxD score at 6 weeks (OR=3.31, 95% CI 1.63, 6.14, p=0.001) was significantly 
associated with the 30 week EF score. Similar results were obtained in the Mild HG and Severe HG 
groups; OR=2.70, 95% CI 1.07, 6.86, p=0.036 and OR=3.80, 95% CI 1.17, 12.4, p=0.027 
respectively. Further, SxD scores at 18 weeks were significantly associated with the 30 week EF 
score in the total, Mild and Severe HG groups; OR=5.13, 95% CI 2.43, 10.8, p<0.001,  OR=4.49, 95% 
CI 1.90, 13.1, p=0.001 and OR=5.46, 95% CI 1.50, 19.9, p=0.010) respectively. The area under the 
ROC curve indicated the ability of these models to discriminate change in EF was fair in Severe HG 
(area under ROC curve: 0.74) but poor in the Mild and Total HG groups (area under ROC curve 0.63 
and 0.66 respectively). In the Severe HG group, the area under the curve in 35 men with SxD IIEF 
score <5 was 0.91 but in 38 men with SxD ≥5 the corresponding value was 0.64.  
 
Discussion. 
Testosterone is critical in the maintenance of male sexual function though the mechanisms by which it 
influences domains such as SxD and EF and, how improvements in one domain are associated with 
improvements in others are unclear [12]. We considered three aspects of the relationship between 
these variables. Firstly, by comparing proportions (rather than mean scores) of men showing 
improved SxD and EF with those that did not, we showed that TRT is significantly associated with 
improved SxD in a significantly greater proportion of men than placebo after 6 weeks while 
corresponding improvement in EF occurs later at 30 weeks. These observations were particularly 
evident in the Severe HG group. While we previously showed changes in mean IIEF domain scores 
[7], this study addressed the issue of the probability of individuals in the groups demonstrating 
improvement. Secondly, we showed that change in SxD was significantly associated with change in 
EF, though only 33.8% of men in the HG/TU demonstrated improvements in both domains (compared 
with 15.6% in the HG/P group). Thirdly, we showed change in SxD at 6 weeks is predictive of EF 
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change after 30 weeks with the area under the ROC curve indicating fair discriminatory ability in men 
with Severe HG and excellent ability in the subgroup with SxD IIEF score <5. Importantly, these 
associations are independent of TRT and show the important role of SxD in predicting EF. 
The prevalence of symptoms such as SxD and EF increased with TT <15.0nmol/l and <8.0nmol/l 
respectively [5]. Further, Yassin and Saad [6] reported that while all 22 diabetic men given TRT 
showed improved IIEF SxD scores, EF improved in only 54% men after 24 weeks. They speculated 
that the delay in changing EF resulted from a direct effect of testosterone on erectile tissue. These 
findings demonstrate the considerable heterogeneity in the HG group. For example, while we found 
that only 51.3% and 47.5% of HG/TU patients given TU for 30 weeks showed improved SxD and EF 
scores respectively (Table 2) and 33.8% improvement in both domains (Table 3), the corresponding 
proportions in the Severe HG men given TU were 74.0%, 63.0% and 63.0% respectively. TU had 
relatively much less impact in the Mild HG group; only 18.9% of the TU-treated and 18.8% of 
untreated men demonstrated an increase in both domains. 
The testosterone levels that effect improvements in SxD and EF may help interpret the results of 
recent studies. The Testosterone trial was carried out in 790 men with HG (TT< 9.5nmol) aged ≥ 65 
years randomised to either 1% transdermal testosterone gel or placebo for 12 months [13].  The 
original publication [13] and a more detailed analysis of the sexual function arm in 470 men by 
Cunningham et al [8] showed that though significant improvement was seen in EF, benefit was mild 
and quoted to be less than expected with phosphodiesterase 5 inhibitors [8, 13, 14] despite men with 
HG having been excluded from the major PDE5I studies. Efficacy rates for PDE5is are little better 
than 50% in T2DM [14]. Our HG group with T2DM did not show significant improvement in EF 
(p=0.61) following TU perhaps because the TT inclusion criterion was ≤ 12nmol/l rather than < 
9.5nmol/l. In the Severe HG group (TT < 8nmol/l) we found significant improvement in EF (p=0.004). 
This suggests re-analysis of the T trial data in men with TT <8nmol/l may show greater benefit in EF. 
Cunningham et al [8] also showed that improvement in SxD and sexual activity was related to the 
increase in testosterone and oestradiol levels. We could not carry out a similar analysis as TT levels 
measured were pre TU administration (trough levels). Importantly, our cohort differed from that of the 
T Trial in baseline characteristics including testosterone preparations, mean age (P: 71.8 years, 
treatment: 71.4 years) and diabetes (P: 35.6%, treatment: 33.8%). 
Various meta-analyses have come to different conclusions on the impact of TRT on sexual function. 
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Corona et al [15] confirmed TRT improved ED and SxD but did not explore the inter-relationships. 
Gianatti et al [16] found conflicting data and recently, Huo et al [17] reviewed 156 eligible studies 
concluding that use of TRT to improve sexual function was without support from clinical trials. Our 
study in men experiencing changes in sexual function following treatment offers further insight. It 
confirms previous observations by us and others regarding which men are most likely to benefit from 
TRT (7). Furthermore, change in SxD after 6 weeks is predictive of later EF change. Thus, further 
study is required to determine the nature of the relationship between change in SxD and EF. 
 
Study limitations and strengths. 
Though our study is based on well characterised men, the total numbers available were relatively 
small, allowing only limited statistical analysis of subgroups. This also prevented us from studying the 
effects of TRT in men stratified by SxD and EF categories. Despite this significant strengths were 
present in the RCT that could direct further research. All TU injections were administered by diabetes 
nurses providing accurate information on dosing and compliance. Clearly, the impact of TRT on 
sexual function domains is mediated by the extent of pathology and treatment duration. Obtaining a 
better understanding of the efficacy of treatment with TU requires study of patient subgroups 
particularly those with men with Severe HG and low sexual function domain scores. Further, 
prospective studies need to be designed to establish whether the relationship between SxD and EF 
has a mechanistic basis.  
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Table 1. Baseline and end of study (30 weeks) variables in men randomised into HG/P and HG/TU groups and allocated to Mild and Severe HG groups using 
trough TT and FT levels.  
 
Unpaired t-tests were carried out to compare differences between the groups for continuous variables (age, TT, SHBG, FT) and rank sum performed when 
the data was ordinal (IIEF SxD and EF scores).  
Paired t-tests showed that at 30 weeks, mean trough TT and FT levels in each TU group had increased significantly (HG/TU: p=0.0002, Mild HG/TU: 
p=0.0056, Severe HG/TU: p=0.013) compared with corresponding baseline values. No such changes were observed in the P counterparts. 
  
HG/P HG/TU p Mild HG/P Mild HG/TU p Severe HG/P Severe HG/TU p
Baseline Data (n=103) (n=86) (n=51) (n=56) (n=52) (n=30)
age: mean/SD (years) 61.5 / 9.8 61.7 / 10.6 0.90 61.8 / 9.7 60.3 / 10.2 0.46 61.1 / 9.9 64.0 / 11.1 0.24
TT: mean/SD (nmol/l) 9.0 / 3.7 9.4 / 3.1 0.43 10.8 / 3.9 10.5 / 2.8 0.58 7.2 / 2.5 7.4 / 2.7 0.75
FT: mean/SD (nmol/l) 0.18 / 0.06 0.19 / 0.06 0.56 0.21 / 0.06 0.21 / 0.05 0.98 0.16 / 0.05 0.15 / 0.06 0.55
SHBG: mean/SD (nmol/l) 29.9 / 14.0 30.8 / 13.8 0.66 34.3 / 15.6 31.7 / 14.7 0.39 25.6 / 10.7 29.2 / 12.1 0.18
IIEF SxD: mean/median (range) 5.3 / 5.0 (2-10) 5.0 / 5.0 (0-9) 0.55 5.5 / 6 (2-10) 5.5 / 5 (2-9) 0.93 5.0 / 5 (2-10) 4.1 / 4 (0-7) 0.16
IIEF EF:mean/median (range) 11.14 / 10.0  (0-30) 10.0 / 0 - 30 0.26 12.6 / 13 (1-30) 13.8 / 11 (1-30) 0.41 10.3 / 6.5 (0-30) 9.3 / 6 (0-25) 0.81
Study End (30 weeks) (n=96) (n=80) (n=48) (n=53) (n=48) (n=27)
TT: mean/SD (nmol/l) 9.6 / 4.5 11.3 / 4.1 0.01 11.3 / 4.8 11.9 / 3.9 0.44 7.9 / 3.4 9.9 / 4.1 0.026
FT: mean/SD (nmol/l) 0.18 / 0.06 0.23 / 0.08 <0.0001 0.21 / 0.07 0.24 / 0.07 0.021 0.16 / 0.05 0.22 / 0.09 0.0009
SHBG: mean/SD (nmol/l) 29.5 / 15.3 29.5 / 12.0 0.98 34.0 / 16.1 31.8 / 12.4 0.46 25.0 / 13.2 25.0 / 10.0 1.00
IIEF SxD: mean/median (range) 4.8 / 2.5 (0-10) 5.5 / 2.3 (0-10) 0.054 4.9 / 2.3 (0-10) 5.4 / 2.2 (0-10) 0.24 4.8 / 2.6 (0-10) 5.7 / 2.5 (0-9) 0.090
IIEF EF:mean/median (range) 10.0 / 10.3 (0-30) 12.9 / 10.3 (0-30) 0.021 11.0 / 10.3 (0-30) 12.8 / 10.6 (0-30) 0.25 9.0 / 10.4 (0-30) 13.0 / 10.6 (1-29) 0.065
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Table 2. Percentages of patients with improved IIEF SxD and EF scores at 6, 18 and 30 weeks in the randomised HG/P and HG/TU groups and groups 
stratified by TT and FT levels into Mild HG and Severe HG.  
 
Chi
2
 tests were performed to test between group proportions of patients showing increased IIEF SxD and EF scores at each of the time points. 
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Table 3. Tabulated data of patients demonstrating changes in IIEF SxD and EF scores in the HG/TU, 
HG/P, Mild HG/TU, Mild HG/P, Severe HG/TU and Severe HG/P men after 30 weeks.  
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Table 4. Logistic regression models showing association between SxD change at 6 weeks and EF 
change at 30 weeks. 
 
 
 
Change in EF after 30 weeks was significantly associated with change in SxD after 6 weeks in TU 
(OR: 3.02, 95% CI: 1.16 – 7.87, p=0.023) and P (OR: 3.55, 95% CI: 1.21 – 10.37, p=0.021) groups, 
the analyses including age.  
Total Group
 (r2 = 0.069) OR (95% CI) p
Age 1.01 (0.98 - 1.04) 0.60
TU (ref: P) 1.43 (0.72 - 2.81) 0.30
Increase in SxD (ref: no change/decrease) - 6 weeks 3.31 (1.63 - 6.74) 0.001
Mild HG
 (r2 = 0.043)
Age 0.99 (0.94 - 1.03) 0.56
TU (ref: P) 0.84 (0.0.35 - 2.05) 0.71
Increase in SxD (ref: no change/decrease) - 6 weeks 2.70 (1.07 - 6.86) 0.036
Severe HG
 (r2 = 0.15)
Age 1.03 (0.98 - 1.08) 0.30
TU (ref: P) 2.84 (0.91 - 8.81) 0.07
Increase in SxD (ref: no change/decrease) - 6 weeks 3.80 (1.17 - 12.4) 0.027
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Figure 1. Recruitment and protocol of the BLAST study. 
 
 
Screen failures (n=12): 
Elevated PSA: 10 (BPH: 9, Prostatic carcinoma: 1), Atrial fibrillation: 1, Withdrawal of consent: 1 
Failure to complete study (n=10): 
Serious adverse events: 4 (treatment unrelated deaths: 3, Prostatic carcinoma: 1 (on placebo). 
Withdrawal of consent: 6
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Figure 2a: Proportion of patients demonstrating improved SxD and EF scores in the Mild HG/P and 
Mild HG/TU groups 
 
 
Figure 2b: Proportion of patients demonstrating improved SxD and EF scores in the Severe HG/P and 
Severe HG/TU groups
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